Adds article type

Review: Should we screen for asymptomatic coronary artery disease in the community?

ND Gollop, The Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, United Kingdom
SF Smith, School of Clinical Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, CB2 0SP, United Kingdom


Introduction: Coronary artery disease (CAD) is the accumulation of atherosclerotic plaque in the coronary arteries; resulting in limited myocardial perfusion. CAD has high levels of global morbidity and mortality and is well researched. Asymptomatic coronary artery disease (ACAD) is the precursor subclinical state and is inadequately detected and researched. The aim of this article was to cross-examine the current research on ACAD. Emphasis was placed on methods of assessment and screening of ACAD.

Materials and Methods: A review of the literature was completed following a structured protocol; search engines, inclusion and exclusion criteria were defined a priori.

Results: Forty-eight articles met all inclusion criteria and were retrieved for detailed analysis. Outcome-based evidence suggested that cardiovascular disease risk stratification followed by imaging based assessments in low-to-moderate risk candidates were shown to be of clinical value in ACAD. A ‘treat all’ primary preventative approach was shown to be of most benefit; however the social and financial implications of this remain unclear.

Conclusions: Effective management of ACAD is essential to lower the worldwide incidence, morbidity and mortality of CAD. Further outcome-based evidence highlighting the benefits of identification, screening and early primary prevention of ACAD is urgently needed.

Keywords: Asymptomatic coronary artery disease, asymptomatic coronary atherosclerosis, subclinical coronary artery disease, subclinical coronary atherosclerosis, asymptomatic coronary artery disease screening, asymptomatic coronary artery disease investigations, asymptomatic coronary artery disease management

Figure 1
Figure 2

1. Bonow, R. O. (2002). ‘Primary Prevention of Cardiovascular Disease - A Call to Action.’ Circulation, 106, 3140-3141. doi: 10.1161/01.CIR.0000048067.86569.E1
2. Hansson, G. K. (2005). ‘Inflammation, Atherosclerosis, and Coronary Artery Disease’. New England Journal of Medicine, 352, 1685-1695. DOI: 10.1056/NEJMra043430
3. Libby, P. Theroux, P. (2005). ‘Pathophysiology of Coronary Artery Disease.’ Circulation, 111, 3481-3488. doi: 10.1161/CIRCULATIONAHA.105.537878
4. Gibbons, R. J. Jones, D. W. Gardener, T. J. Goldstein, L. B. Moller, J. H. Yancy, C. W. (2008). ‘The American Heart Association’s 2008 statement of principles for healthcare reform’. Circulation, 118, 2209-2218. doi: 10.1161/CIRCULATIONAHA.108.191092
5. Shah, P. K. (2010). ‘Screening Asymptomatic Subjects for Subclinical Atherosclerosis’. Journal of the American College of Cardiology, 56 (2), 98-105. doi:10.1016/j.jacc.2009.09.081

6. Pearson, T. A. Mensah, G. A. Alexander, R. W. Anderson, J. L. Cannon III, R. O. Criqui, M. Fadl, Y. Y. Fortmann, S. P. Hong, Y. Myers, G. L. Rifai, N. Smith Jr, S. C. Taubert, K. Tracy, R. P. Vinicor, F. (2003). ‘Markers of Inflammation and Cardiovascular Disease’. Circulation, 107, 499-511. doi: 10.1161/01.CIR.0000052939.59093.45
7. Budoff, M. J. Gu, K. M. (2008). ‘Expert review on coronary calcium.’ Vascular Health Risk Management, 4 (2), 315–324.
8. Galkina, E. Ley, K. (2009). Immune and Inflammatory Mechanisms of Atherosclerosis. Annual Reviews of Immunology; 27: 165-197 DOI: 10.1146/annurev.immunol.021908.132620
9. Glass, C. K. and Witztum, J. L. (2001). ‘Atherosclerosis: The Road Ahead Review’. Cell, 104, 503–516. doi:10.1016/S0092-8674(01)00238-0
10. Li, X. Liu, Y. Zhang, H. Ren, L. Li, Q. Li, N. (2011). ‘Animal models for the atherosclerosis research: a review.’ Protein Cell, 2 (3), 189–20. doi: 10.1007/s13238-011-1016-3
11. D'Agostino, R. B. Russell, M. W. Huse, D. M. Ellison, C. Silbershatz, H. Wilson, P. W. F. Hartz, S. C. (2000). ‘Primary and subsequent coronary risk appraisal: New results from the Framingham study’. American Heart Journal, 139 (2-1), 272-281
12. Anand, S. S. Islam, S. Rosengren, A. Franzosi, M. G. Steyn, K. Yusufali, A. H. Keltai, M. Diaz, R. Rangarajan, S. Yusuf, S. (2008). ‘Risk factors for myocardial infarction in women and men: insights from the INTERHEART study’. European Heart Journal, 29 (7), 932-940. doi: 10.1093/eurheartj/ehn018
13. Ambrose, J. A. Barua, R. S. (2004). ‘The pathophysiology of cigarette smoking and cardiovascular disease: An update.’ Journal of the American College of Cardiology, 43 (10), 1731–1737. doi:10.1016/j.jacc.2003.12.047
14. Ridker, P. M. Rifai, N. Cook, N. R. Bradwin, G. Buring, J. E. (2005). ‘Non–HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women.’ Journal of the American Medical Association, 294 (3), 326-333. doi:10.1001/jama.294.3.326
15. Sowers, J. R. Epstein, M. Frohlich, E. D. (2001). ‘Diabetes, Hypertension, and Cardiovascular Disease: An Update.’ Hypertension, 37, 1053-1059. doi: 10.1161/01.HYP.37.4.1053
16. Van Gaal, L. F. Mertens, I. L. De Block, C. E. (2006). ‘Mechanisms linking obesity with cardiovascular disease.’ Nature, 444, 875-880. doi:10.1038/nature05487
17. Williams RB, Barefoot JC, Schneiderman N. Psychosocial risk factors for cardiovascular disease: more than one culprit at work. JAMA. 2003 Oct 22;290(16):2190-2. doi:10.1001/jama.290.16.2190.
18. Bazzano, L. A. Serdula, M. K. Liu, S. (2003). ‘Dietary intake of fruits and vegetables and risk of cardiovascular disease.’ Current Atherosclerosis Reports, 5 (6), 492-499. DOI 10.1007/s11883-003-0040-z
19. Murray, R. P. Connett, J. E. Tyas, S. L. Bond, R. Ekuma, O. Silversides, C. K. Barnes, G. E. (2002). ‘Alcohol Volume, Drinking Pattern, and Cardiovascular Disease Morbidity and Mortality: Is There a U-shaped Function?’ American Journal of Epidemiology, 155 (3), 242-248. doi: 10.1093/aje/155.3.242
20. Franco, O. H. de Laet, C. Peeters, A. Jonker, J. Mackenbach, J. Nusselder, W. (2005). ‘Effects of Physical Activity on Life Expectancy With Cardiovascular Disease.’ JAMA, 165 (20), 2355-2360. doi:10.1001/archinte.165.20.2355.
21. Taylor, A. J. Feuerstein, I. Wong, H. Barko, W. Brazaitis, M. O'Malley, P. G. (2001). ‘Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project’. American Heart Journal, 141 (3), 463-468. doi:10.1067/mhj.2001.113069
22. Desai, M. Y. Nasir, K. Braunstein, J. B. Rumberger, J. A. Post, W. S. Budoff, M. J. Blumenthal, R. S. (2004). ‘Underlying risk factors incrementally add to the standard risk estimate in detecting subclinical atherosclerosis in low- and intermediate-risk middle-aged asymptomatic individuals’. American Heart Journal; 148 (5): 871-7.
23. Kronmal, R. A. McClelland, R. L. Detrano, R. Shea, S. Lima, J. A. Cushman, M. Bild, D. E. Burke, G. L. (2007). Risk Factors for the Progression of Coronary Artery Calcification in Asymptomatic Subjects Results From the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation; 115: 2722-2730. doi: 10.1161/CIRCULATIONAHA.106.674143

24. Virmani, R. Burke, A. P. Farb, A. Kolodgie, F. D. (2006). ‘Pathology of the Vulnerable Plaque’. Journal of the American College of Cardiology, 47 (8), C13–C18. doi:10.1016/j.jacc.2005.10.065
25. Osula, S. Bell, G. M. Hornung, R. S. (2002). ‘Acute myocardial infarction in young adults: causes and management’. Postgrad Medical Journal, 78, 27-30. doi:10.1136/pmj.78.915.27
26. Chan MY, Woo KS, Wong HB, Chia BL, Sutandar A, Tan HC. Antecedent risk factors and their control in young patients with a first myocardial infarction. Singapore Med J. 2006 Jan;47(1):27-30.
27. Matharu, G. S, Buckley, C. D. (2012). ‘Performing a literature review’. Student BMJ 2012;20:e404 DOI: 10.1136/sbmj.e404
28. Faergeman, O. (2002). Methods for detecting coronary disease: epidemiology and clinical management. Acta Physiol Scand; 176 (2): 161-5. DOI: 10.1046/j.0001-6772.2002.01019.x
29. Greenland, P. LaBree, L. Azen, S. P. Doherty, T. M. Detrano, R. C. (2004). ‘Coronary Artery Calcium Score Combined With Framingham Score for Risk Prediction in Asymptomatic Individuals.’ Journal of the American Medical Association, 291 (2), 210-215. doi:10.1001/jama.291.2.210.
30. Okwuosa, T.M. Greenland, P. Ning, H. Liu, K. Lloyd-Jones, DM. (2012). Yield of screening for coronary artery calcium in early middle-age adults based on the 10-year Framingham Risk Score: the CARDIA study. JACC Cardiovasc Imaging; 5 (9): 923-30. DOI: 10.1016/j.jcmg.2012.01.022

31. Nasir, K. Michos, E.D. Blumenthal, R.S. Raggi, P. (2005). ‘Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines’. Journal of the American College of Cardiology, 46, 1931–1936.
32. Villines, T.C. (2012). Statin therapy for subclinical atherosclerosis in primary prevention: time to prove it? JACC Cardiovasc Imaging; 5 (3): 261-3. DOI: 10.1016/j.jcmg.2011.11.015
33. Caymaz, H.O. Yüksel, G. (2008). Fate of incidental, asymptomatic lesions discovered during percutaneous coronary intervention. Angiology; 59 (2): 193-7. doi: 10.1177/0003319707303889
34. Jacobs, P.C. Gondrie, M.J. Mali, W.P. Oen, A.L. Prokop, M. Grobbee, D.E. van der Graaf, Y. (2011). Unrequested information from routine diagnostic chest CT predicts future cardiovascular events. Eur Radiol; 21 (8): 1577-85. doi: 10.1007/s00330-011-2112-8
35. Glaser, R. Selzer, F. Faxon, D.P. Laskey, W.K. Cohen, H.A. Slater, J. Detre, K.M. Wilensky, R.L. (2005). Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation; 111 (2): 143-9. doi: 10.1161/01.CIR.0000150335.01285.12

36. Raggi, P. (2009). Cardiac CT in asymptomatic patients at risk. Cardiol Clin;27 (4): 605-10. doi: 10.1016/j.ccl.2009.06.003
37. O'Malley, P. G. Taylor, A. J. Jackson, J. L. Doherty, T. M. Detrano, R. C. (2000). Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. American Journal of Cardiology, 85 (8): 945-8.
38. Shaw, L. J. Raggi, P. Schisterman, E. Berman, D. S. Callister, T. Q.(2003). ‘Prognostic Value of Cardiac Risk Factors and Coronary Artery Calcium Screening for All-Cause Mortality.’ Radiology, 228, 826-833. doi: 10.1093/eurheartj/ehi750
39. Raggi, P. Gongora, M. C. Gopal, A. Callister, T. Q. Budoff, M. Shaw, L. J. (2008). ‘Coronary Artery Calcium to Predict All-Cause Mortality in Elderly Men and Women.’ Journal of the American College of Cardiology, 52 (1), 17–23. doi:10.1016/j.jacc.2008.04.004
40. Maki, K.C. Davidson, M.H. Dicklin, M.R. Bell, M. Witchger, M. Feinstein, S.B. (2011). Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. J Clin Lipidol; 5 (3): 141-51. doi: 10.1016/j.jacl.2011.02.003
41. Mahfouz, R.A. El Tahlawi, M.A. Ateya, A.A. Elsaied, A. (2011). Early detection of silent ischemia and diastolic dysfunction in asymptomatic young hypertensive patients. Echocardiography; 28 (5): 564-9. doi: 10.1111/j.1540-8175.2011.01388.x
42. Stein, J.H. Korcarz, C.E. Hurst. R.T. et al., (2008). ‘Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine. Journal of the American Society of Echocardiography, 21, 93–111. doi: 10.1016/j.echo.2007.11.011.
43. Schneer, S. Bachar, G.N. Atar, E. Koronowski, R. Dicker, D. (2013). Evaluation of framingham and systematic coronary risk evaluation scores by coronary computed tomographic angiography in asymptomatic adults. Am J Cardiol; 111 (5): 700-4. doi: 10.1016/j.amjcard.2012.11.023
44. Pakkal, M. Raj, V. McCann, G.P. (2011). Non-invasive imaging in coronary artery disease including anatomical and functional evaluation of ischaemia and viability assessment. Br J Radiol; 84 Spec No 3: S280-95. doi: 10.1259/bjr/50903757
45. Madaj, P. Budoff, M.J. (2012). Risk stratification of non-contrast CT beyond the coronary calcium scan. J Cardiovasc Comput Tomogr; 6 (5): 301-7. doi: 10.1016/j.jcct.2012.02.008
46. Kim, K. P. Einstein, A. J. Berrington de Gonzalez, A. (2009). ‘Coronary artery calcification screening: estimated radiation dose and cancer risk.’ Archives of Internal Medicine, 169, 1188-1194. doi: 10.1001/archinternmed.2009.162
47. Toth, P.P. (2008). Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract; 62 (8): 1246-54. doi: 10.1111/j.1742-1241.2008.01804.x
48. Eleid, M.F. Lester, S.J. Wiedenbeck, T.L. Patel, S.D. Appleton, C.P. Nelson, M.R. Humphries, J. Hurst, R.T. (2010). Carotid ultrasound identifies high risk subclinical atherosclerosis in adults with low framingham risk scores. J Am Soc Echocardiogr; 23 (8): 802-8. doi: 10.1016/j.echo.2010.06.003
49. Naqvi, T.Z. Mendoza, F. Rafii, F. Gransar, H. Guerra, M. Lepor, N. Berman, D.S. Shah, P.K. (2010). High prevalence of ultrasound detected carotid atherosclerosis in subjects with low Framingham risk score: potential implications for screening for subclinical atherosclerosis. J Am Soc Echocardiogr;23(8):809-15. doi: 10.1016/j.echo.2010.05.005

50. Grundy, S.M. Cleeman, J.I. Merz, C.N. et al. (2004). ‘Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines’. Circulation, 110, 227–239. doi: 10.1161/01.CIR.0000133317.49796.0E
51. Kones, R. (2011). Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther; 5: 325-80. doi: 10.2147/DDDT.S14934
52. Hoff, J. A. Chomka, E. V. Krainik, A. J. Daviglus, M. Rich, S. Kondos, G. T. (2001). ‘Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults.’ The American Journal of Cardiology, 87 (12), 1335–1339.
53. Cole JH, Miller JI 3rd, Sperling LS, Weintraub WS. Long-term follow-up of coronary artery disease presenting in young adults. J Am Coll Cardiol. 2003 Feb 19;41(4):521-8. Doi: /10.1016/S0735-1097(02)02862-0
54. Rubin, J.B. Borden, W.B. (2012). Coronary heart disease in young adults. Curr Atheroscler Rep; 14 (2): 140-9. doi: 10.1007/s11883-012-0226-3.

55. Hingorani, A. D. Psaty, B. M. (2009). ‘Primary Prevention of Cardiovascular Disease. Time to Get More or Less Personal?’ Journal of the American Medical Association, 302 (19), Commentary. doi:10.1001/jama.2009.1698.
56. Katić, T. Sakić, I. Bergovec, M. (2009). ‘Primary prevention of cardiovascular disease.’ Acta Med Croatica, 63 (1), 71-4.
57. Hecht, H.S. (2012). Subclinical atherosclerosis imaging comes of age: coronary artery calcium in primary prevention. Curr Opin Cardiol;27(5):508-14. doi: 10.1097/HCO.0b013e328356af2d.
58. Polonsky, T.S. Greenland, P. (2012). CVD screening in low-risk, asymptomatic adults: clinical trials needed. Nat Rev Cardiol; 9 (10): 599-604. doi: 10.1038/nrcardio.2012.114.
59. Bartolucci, A.A. Tendera, M. Howard, G. (2011). Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol; 107 (12): 1796-801. doi: 10.1016/j.amjcard.2011.02.325

60. Wald, N. J. Law, M. R. (2003). ‘A strategy to reduce cardiovascular disease by more than 80%’. British Medical Journal, 326, 1419. Doi: 10.1136/bmj.326.7404.1419
61. Stampfer, M. J. Hu, F. B. Manson, J. E. Rimm, E. B. Willett, W. C. (2000). ‘Primary Prevention of Coronary Heart Disease in Women through Diet and Lifestyle’. New England Journal of Medicine, 343, 16-22. DOI: 10.1056/NEJM200007063430103
62. Schwartz, J. Allison, M.A. Rifkin, D.E. Wright, C.M. (2012). Influence of patients' coronary artery calcium on subsequent medication use patterns. Am J Health Behav;36 (5): 628-38. doi: 10.5993/AJHB.36.5.5
63. Mora, S. Ridker, P. M. (2006). ‘Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?’ American Journal of Cardiology, 97 (2-1), 33–41.
64. Domanski, M. Lloyd-Jones, D. Fuster, V. Grundy, S. (2011). Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol; 8 (12): 721-5. doi: 10.1038/nrcardio.2011.158
65. Ebrahim, S. Beswick, A. Burke, M. Davey Smith, G. (2006). ‘Multiple risk factor interventions for primary prevention of coronary heart disease.’ Cochrane Database of Systematic Reviews, Issue 4, 1-51. doi: 10.1002/14651858.CD001561.pub3
66. Hippisley-Cox, J. Coupland, C. Vinogradova, Y. Robson, J. Minhas, R. Sheikh, A. Brindle, P. (2008). ‘Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2’. BMJ; 336 (7659): 1475-82. doi: 10.1136/bmj.39609.449676.25
67. Erbel, R. Möhlenkamp, S. Moebus, S. Schmermund, A. Lehmann, N. Stang, A. Dragano, N. Grönemeyer, D. Seibel, R. Kälsch, H. Bröcker-Preuss, M. Mann, K. Siegrist, J. Jöckel, K.H; Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol;56(17):1397-406. doi: 10.1016/j.jacc.2010.06.030
68. Ferket, B.S. Genders, T.S. Colkesen, E.B. Visser, J.J. Spronk, S. Steyerberg, E.W. Hunink, M.G. (2011). Systematic review of guidelines on imaging of asymptomatic coronary artery disease. J Am Coll Cardiol;57(15):1591-600. doi: 10.1016/j.jacc.2010.10.055.
69. Bhagirath, K.M. Hurst, R.T. Lester, S.J. (2012). Cardiovascular risk assessment in the asymptomatic individual: a case-based approach. Coron Artery Dis; 23 (4): 298-302. doi: 10.1097/MCA.0b013e3283526ac1.

70. Lewis, S. Gollop, N. D. (2013). The numbers expected to be treated (NETT): a way forward in CVD prescribing? Prim Care Cardiovasc J; 6: 32-36. DOI:10.3132/pccj.2012.060
71. Kalia, N.K. Miller, L.G. Nasir, K. Blumenthal, R.S. Agrawal, N. Budoff, M.J. (2006). ‘Visualizing coronary calcium is associated with improvements in adherence to statin therapy’. Atherosclerosis, 185, 394–399. doi:10.1016/j.atherosclerosis.2005.06.018
72. Orakzai, R.H. Nasir, K. Orakzai, S.H. et al., (2008). ‘Effect of patient visualization of coronary calcium by electron beam computed tomography on changes in beneficial lifestyle behaviors’. 101, 999–1002. doi: 10.1016/j.amjcard.2007.11.059
73. Karim, R. Hodis, H.N. Detrano, R. Liu, C.R. Liu, C.H. Mack, W.J. (2008). ‘Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites’. The American Journal of Cardiology, 102, 825–830. doi: 10.1016/j.amjcard.2008.05.039

74. Akosah, K.O. S.A., Cogbill, C. Schoenfeld, P. (2003). ‘Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?’ Journal of the American College of Cardiology, 41, 1475-9. DOI: 10.1016/S0735-1097(03)00187-6
75. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK; SHAPE Task Force. Am J Cardiol. 2006 Jul 17;98(2A):2H-15H. Epub 2006 Jun 12. Review. doi:10.1016/j.amjcard.2006.03.002
76. See, R. Lindsey, J. B. Patel, M. J. et al. (2008). ‘Application of the Screening for Heart Attack Prevention and Education Task Force recommendations to an urban population: observations from the Dallas Heart Study.’ Archives of Internal Medicine, 168, 1055–1062. doi:10.1001/archinte.168.10.1055

77. Otero, H. J. Rybicki, F. J. Greenberg, D. Mitsouras, D. Mendoza, J. A. Neumann, P. J. (2010). Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money? International Journal of Cardiovascular Imaging; 26 (6): 605-12. doi: 10.1007/s10554-010-9634-z.
78. Powell, E. S. Patterson, B. W. Venkatesh, A. K. Khare, R. K. (2012). ‘Cost-effectiveness of a novel indication of computed tomography of the coronary arteries’. Critical Pathways in Cardiology; 11 (1): 20-5. doi: 10.1097/HPC.0b013e318246854c.
79. Narula, J. Garg, P. Achenbach, S. Motoyama, S. Virmani, R. Strauss, H.W. (2008). Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med; 5 Suppl 2: S2-10. doi: 10.1038/ncpcardio1247
80. Motoyama, S. Sarai, M. Harigaya, H. Anno, H. Inoue, K. Hara, T. Naruse, H. Ishii, J. Hishida, H. Wong, N. D. Virmani, R. Kondo, T. Ozaki, Y. Narula, J. (2009). ‘Computed Tomographic Angiography Characteristics of Atherosclerotic Plaques Subsequently Resulting in Acute Coronary Syndrome.’ Journal of the American College of Cardiology, 54 (1), 49–57 doi: 10.1016/j.jacc.2009.02.068.
81. DeFilippis, A.P. Blaha, M.J. Ndumele, C.E. Budoff, M.J. Lloyd-Jones, D.M. McClelland, R.L. Lakoski, S.G. Cushman, M. Wong, N.D. Blumenthal, R.S. Lima, J. Nasir, K. (2011). The association of Framingham and Reynolds risk scores with incidence and progression of coronary artery calcification in MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol; 58 (20): 2076-83. doi: 10.1016/j.jacc.2011.08.022
82. Lakoski, S. G. Greenland, P. Wong, N. D. Schreiner, P. J. Herrington, D. M. Kronmal, R. A. Liu, K. Blumenthal, R. S. (2007). ‘Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as “Low Risk” Based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA).’ Archives of Internal Medicine, 167 (22), 2437-2442. doi:10.1001/archinte.167.22.2437

Abstracts from the ATRIUM 2014 conference

Richard Heywood, Editor, Cambridge Medicine Journal.
Organisers of the ATRIUM conference

We are pleased to be able to publish the abstracts from the 6th Annual National ATRIUM Conference, which took place on 22nd February 2014 at the Chancellor’s Building, New Royal Infirmary of Edinburgh. This annual conference is organised by ATRIUM, a student-run organisation at the University of Edinburgh which aims to encourage research amongst undergraduate medical students. Their website is

There were a mixture of oral and poster presentations, which are listed below. The name of the presenting student is in bold.

Oral presentations

Optogenetics: A Vision of the Future of Neurology?

Fraser Brown, 3rd year Medical Student, University of Edinburgh, UK.

In 1979, Nobel laureate Francis Crick published a paper discussing progress in neuroscience. Describing the subject as “profoundly mysterious”, he speculated on new methods of investigating the brain, including the ability to inactivate one type of neuron whilst leaving the others “more or less unaltered” [1]. Crick is not alone; for years the mammalian brain has dumbfounded researchers [1,2]. In the human, a hundred billion neuronal parts and myriad connections lead to an interconnected system of a level of unparalleled complexity [3].


1. Crick F. H. C. Thinking about the brain. Sci. Am. 1979.

2. Deisseroth K. Controlling the brain with light. Sci Am. 2010 303(5):48-55.

3. Koch C, Laurent G. Complexity and the nervous system. Science. 1999 2;284(5411):96-8. DOI:10.1126/science.284.5411.96

4. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R,Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe. Eur Neuropsychopharmacol. 2011 21(9):655-79. DOI:10.1016/j.euroneuro.2011.07.018

5. Williams S. C. P, Deisseroth K. Optogenetics. Proc. Natl. Acad. Sci. USA. 2013 110(41):16287 DOI:10.1073/pnas.1317033110

6. Harz H, Hegemann P. Rhodopsin-regulated calcium currents in Chlamydomonas. Nature 1991 351(6326):489–491. DOI:10.1038/351489a0

7. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K (2005) Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci 8(9):1263–1268. DOI:10.1038/nn1525

8. Reiner A, Isacoff EY. The Brain Prize 2013: the optogenetics revolution. Trends Neurosci. 2013 Oct;36(10):557-60. DOI:10.1016/j.tins.2013.08.005

9. Tye KM, Prakash R, Kim S, Fenno LE, Grosenick L, Zarabi H, Thompson KR, Gradinaru V, Ramakrishnan C, Deisseroth K. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature. 2011 17; 471(7338): 358–363 DOI:10.1038/nature09820

10. Tye KM, Deisseroth K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nat Rev Neurosci. 2012 20;13(4):251-66. DOI:10.1038/nrn3171

11. Gunaydin LA, Yizhar O, Berndt A, Sohal VS, Deisseroth K, Hegemann P. Ultrafast optogenetic control. Nat Neurosci. 2010 13(3):387-92. DOI:10.1038/nn.2495

12. Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K. Optogenetics in neural systems. Neuron. 2011 14;71(1):9-34. DOI:10.1016/j.neuron.2011.06.004

13. LaLumiere RT. A new technique for controlling the brain: optogenetics and its potential for use in research and the clinic. Brain Stimul. 2011 4(1):1-6. DOI:10.1016/j.brs.2010.09.009

14. Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K, Burger C.Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther. 2006 13(3):63-83. DOI:10.1016/j.ymthe.2005.11.009

15. Diester I, Kaufman MT, Mogri M, Pashaie R, Goo W, Yizhar O, Ramakrishnan C, Deisseroth K, Shenoy KV. An optogenetic toolbox designed for primates. Nat Neurosci. 2011 14(3):387-97. DOI:10.1038/nn.2749

16. González F, Boué S, Izpisúa Belmonte JC. Methods for making induced pluripotent stem cells: reprogramming à la carte. Nat Rev Genet. 2011 12(4):231-42. DOI:10.1038/nrg2937

17. Kravitz AV, Freeze BS, Parker PR, Kay K, Thwin MT, Deisseroth K, Kreitzer AC. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010 29;466(7306):622-6. DOI:10.1038/nature09159

18. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science 2009;324:354-359. DOI:10.1126/science.1167093

19. SH Elsea, RE Lucas The mousetrap: what we can learn when the mouse model does not mimic the human disease. ILAR J 2002 43(2):66-79. DOI:10.1093/ilar.43.2.66

20. Dragunow M. The adult human brain in preclinical drug development. Nat. Rev. Drug Discov. 2008 7(8):659-66. DOI:10.1038/nrd2617

21. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 2006 126(4):663–676 DOI:10.1016/j.cell.2006.07.024

22. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007 30;131(5):861-72. DOI:10.1016/j.cell.2007.11.019

23. Daley GQ. The Promise and Perils of Stem Cell Therapeutics. Cell Stem Cell 2012 10(6):740-9. DOI:10.1016/j.stem.2012.05.010

24. Merkle FT, Eggan K. Modeling Human Disease with Pluripotent Stem Cells: from Genome Association to Function. Cell Stem Cell 2013 6;12(6):656-68. DOI:10.1016/j.stem.2013.05.016

25. Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009 15;457(7227):277-80. DOI:10.1038/nature07677

26. Serio A, Bilican B, Barmada SJ, Ando DM, Zhao C, Siller R, Burr K, Haghi G, Story D, Nishimura AL, Carrasco MA, Phatnani HP, Shum C, Wilmut I, Maniatis T, Shaw CE, Finkbeiner S, Chandran S. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc. Natl. Acad. Sci. USA 2013 110(12):4697-702. DOI:10.1073/pnas.1300398110

27. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW, Schapira AH, Gwinn K, Hardy J, Lewis PA, Kunath T. 2011. Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun. 2011 23;2:440. DOI:10.1038/ncomms1453

28. Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, Semple R, Weber A, Lomas DA, Vallier L. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest. 2010 120(9):3127-36. DOI:10.1172/JCI43122

29. Marchetto MC, Brennand KJ, Boyer LF, Gage FH. Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Hum Mol Genet. 2011 15;20(R2):R109-15 DOI:10.1093/hmg/ddr336

30. Trounson A, Shepard KA, DeWitt ND. Human disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev. 2012 22(5):509-16. DOI:10.1016/j.gde.2012.07.004

31. Tønnesen J. Optogenetic cell control in experimental models of neurological disorders. Behav Brain Res. 2013 15;255:35-43. DOI:10.1016/j.bbr.2013.07.007

32. Demont-Guignard S, Benquet P, Gerber U, Biraben A, Martin B, Wendling F. Distinct hyperexcitability mechanisms underlie fast ripples and epileptic spikes. Ann Neurol. 2012 71(3):342-52. DOI:10.1002/ana.22610

33. Tønnesen J, Sørensen AT, Deisseroth K, Lundberg C, Kokaia M. Optogenetic control of epileptiform activity. Proc Natl Acad Sci U S A. 2009 21;106(29):12162-7. DOI:10.1073/pnas.0901915106

34. Krook-Magnuson E, Armstrong C, Oijala M, Soltesz I. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat Commun. 2013 4:1376. DOI:10.1038/ncomms2376

35. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008 12(4):540-6. DOI:10.1016/j.yebeh.2007.12.019

36. Albert PR. Light up your life: Optogenetics for depression? J Psychiatry Neurosci. 2014 39(1):3-5. DOI:10.1503/jpn.130267

37. Busskamp V, Roska B. Optogenetic approaches to restoring visual function in retinitis pigmentosa. Curr Opin Neurobiol. 2011 21(6):942-6.2011 21(6):942-6. DOI:10.1016/j.conb.2011.06.001

38. Jacobson SG, Sumaroka A, Luo X, Cideciyan AV. Retinal optogenetic therapies: clinical criteria for candidacy. Clin Genet 2013 84: 175–182. DOI:10.1111/cge.12165

39. Lobo MK, Nestler EJ, Covington HE 3rd. Potential utility of optogenetics in the study of depression. Biol Psychiatry. 2012 15;71(12):1068-74. DOI:10.1016/j.biopsych.2011.12.026

40. Manfredsson FP, Bloom DC, Mandel RJ. Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues. Neurobiol Dis. 2012 48(2):212-21. DOI:10.1016/j.nbd.2012.03.001

41. Kravitz AV, Freeze BS, Parker PR, Kay K, Thwin MT, Deisseroth K, Kreitzer AC.Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010 29;466(7306):622-6. DOI:10.1038/nature09159

42. Deisseroth K. Optogenetics. Nat Methods 2011 8:26–29. DOI:10.1038/nmeth.f.324

The Future of Neurology: Announcing the winning essay of the 2014 “Neuroscience to Neurology” essay competition

Faye Begeti, Editor-in-Chief, Cambridge Medicine Journal

The World Health Organization estimates that neurological disorders currently affect one billion people worldwide, a number which is predicted to increase considerably as a result of an ageing population. The need to further understand the brain and make progress in the field of neurology has therefore never been greater. However, with over 100 million neurons each making over 1000 synapses, the human brain is undoubtedly the most complex organ in the human body, and it is this complexity that has meant that advances in neuroscience have been comparatively slow.

CamSurg conference 2014 Abstracts

Richard Heywood, Editor, Cambridge Medicine Journal.

It is our pleasure to once again be able to publish the abstracts for posters presented at the recent CamSurg conference, which took place on Saturday 22nd February, 2014, at Addenbrooke's Hospital in Cambridge. Following on from the successful 2013 conference, CamSurg organised an interesting mix of keynote speakers, workshops and oral and poster presentations. The full programme can be found on the CamSurg website

The following abstracts were put forward for presentation at the conference:

Obstetric ultrasound: A guide for medical students

Stephanie F. Smith, School of Clinical Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0SP
Nicholas D. Gollop, The Norfolk and Norwich University Hospital, Colney Lane, Norwich, NR4 7UY
Christoph Lees, Fetal Medicine, Rosie Maternity, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge. CB2 2QQ

At some point within your medical training, whether it’s during your first Obstetrics attachment or if you venture to the Radiology department, you are likely to encounter the use of Obstetric ultrasound scanning. However, it can be a complex subject to master and is not covered extensively in the undergraduate core curriculum or textbooks. This article discusses the key essentials that will help you make the most of your learning experience in these situations.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

1. Department of Health. Managing high value capital equipment in the NHS in England. National Audit Office. March 2011. Available online at [Accessed 15 May 2013]
2. Collins S, Arulkumaran S, Hayes K, Jackson S, Impey L. Oxford Handbook of Obstetrics and gynaecology, 2nd Ed. Oxford University Press, 2008. pp114.
3. ter Haar G. The new British Medical Ultrasound Society Guidelines for the safe use of diagnostic ultrasound equipment. Ultrasound May 2010 vol. 18 no. 2 50-51 doi: 10.1258/ult.2010.100007

Detection of Coeliac Patients at Risk of an Osteoporotic Fracture: A Two-Cycle Clinical Audit

Adam Charles Nunn, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, United Kingdom
Damian David Patterson, Abbey View Medical Centre, Salisbury Road, Shaftesbury, Dorset SP7 8DH, United Kingdom


Patients diagnosed with Coeliac disease are known to be at higher risk of suffering a low-impact fracture, and even as children it is important to detect and correct malabsorption due to Coeliac since this may have a lasting impact on their lifelong fracture risk. The British Society of Gastroenterologists recommends that those Coeliac patients with two or more additional risk factors for osteoporotic fracture undergo a dual X-ray absorptiometry (DEXA) scan to determine their bone density. This audit addressed the question of whether this standard was being adhered to in a general practice setting in the south-east of England. The capture of cases represented a prevalence of 1:275 (similar to previously reported figures for the prevalence of this condition). The rate of DEXA scanning in this population was disappointingly low (only 37%), and since many of those Coeliac patients who should have been scanned, and were not, possessed ‘minor’ risk factors such as smoking or female gender, the low pick-up rate may be attributable to a lack of awareness of the small but significant risk that these factors pose. Of those DEXA scans performed, the bone mineral densities of the patients concerned was inversely proportional to the number of risk factors they possessed, supporting the stance of the BSG. Practitioner education alone was not sufficient to improve the rate of scanning, which actually declined following a period of raising awareness of the need for such scans.

Figure 1
Figure 2
Figure 3
Figure 4

1. Marsh D, Currie C, Brown P, Cooper A, Elliott J, Griffiths R, Hertz K, Johansen A, McLellan AR, Mitchell P, Parker M, Sahota O, Severn A, Sutcliffe A, Wakeman R. The care of patients with fragility fracture. British Orthopaedic Association 2007.
2. Parker MJ, Anand JK. What is the true mortality of hip fractures? Public Health 1991 Nov;105(6):443-6. DOI: 10.1016/S0033-3506(05)80614-6
3. Burge RT, Worley D, Johansen A, Bhattacharyya S, Bose U. The cost of osteoporotic fractures in the UK: projections for 2000-2020. Journal of Medical Economics 2001;4:51-62. DOI: 10.3111/200104051062
4. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 2003 Aug;15(8):857-64. DOI: 10.1097/00042737-200308000-00004
5. O'Reilly D, Murphy J, McLaughlin J, Bradshaw J, Dean G. The prevalence of coeliac disease and cystic fibrosis in Ireland, Scotland, England and Wales. Int J Epidemiol 1974 Sep;3(3):247-51. DOI: 10.1093/ije/3.3.247
6. West J, Logan RF, Hill PG, Lloyd A, Lewis S, Hubbard R, Reader R, Holmes GK, Khaw KT. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003 Jul;52(7):960-5. DOI: 10.1136/gut.52.7.960
7. Davie MW, Gaywood I, George E, Jones PW, Masud T, Price T, Summers GD. Excess non-spine fractures in women over 50 years with celiac disease: a cross-sectional, questionnaire-based study. Osteoporos Int 2005 Sep;16(9):1150-5. DOI: 10.1007/s00198-004-1822-z
8. Fickling WE, McFarlane XA, Bhalla AK, Robertson DA. The clinical impact of metabolic bone disease in coeliac disease. Postgrad Med J 2001 Jan;77(903):33-6. DOI: 10.1136/pmj.77.903.33
9. Ludvigsson JF, Michaelsson K, Ekbom A, Montgomery SM. Coeliac disease and the risk of fractures - a general population-based cohort study. Aliment Pharmacol Ther 2007 Feb 1;25(3):273-85. DOI: 10.1111/j.1365-2036.2006.03203.x
10. Moreno ML, Vazquez H, Mazure R, Smecuol E, Niveloni S, Pedreira S, Sugai E, Maurino E, Gomez JC, Bai JC. Stratification of bone fracture risk in patients with celiac disease. Clin Gastroenterol Hepatol 2004 Feb;2(2):127-34. DOI: 10.1016/S1542-3565(03)00320-3
11. Vasquez H, Mazure R, Gonzalez D, Flores D, Pedreira S, Niveloni S, Smecuol E, Maurino E, Bai JC. Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J Gastroenterol 2000 Jan;95(1):183-9. DOI: 10.1111/j.1572-0241.2000.01682.x
12. West J, Logan RF, Card TR, Smith C, Hubbard R. Fracture risk in people with celiac disease: a population-based cohort study. Gastroenterology 2003 Aug;125(2):429-36. DOI: 10.1016/S0016-5085(03)00891-6
13. Thomason K, West J, Logan RF, Coupland C, Holmes GK. Fracture experience of patients with coeliac disease: a population based survey. Gut 2003 Apr;52(4):518-22. DOI: 10.1097/00042737-200305000-00031
14. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002 Jul 1;156(1):1-10. DOI: 10.1093/aje/kwf007
15. Corazza GR, Di Stefano M, Maurino E, Bai JC. Bones in coeliac disease: diagnosis and treatment. Best Pract Res Clin Gastroenterol 2005 Jun;19(3):453-65. DOI: 10.1016/j.bpg.2005.01.002
16. Caraceni MP, Molteni N, Bardella MT, Ortolani S, Nogara A, Bianchi PA. Bone and mineral metabolism in adult celiac disease. Am J Gastroenterol 1988 Mar;83(3):274-7.
17. Valdimarsson T, Lofman O, Toss G, Strom M. Reversal of osteopenia with diet in adult coeliac disease. Gut 1996 Mar;38(3):322-7. DOI: 10.1136/gut.38.3.322
18. Sategna-Guidetti C, Grosso SB, Grosso S, Mengozzi G, Aimo G, Zaccaria T, Di Stefano M, Isaia GC. The effects of 1-year gluten withdrawal on bone mass, bone metabolism and nutritional status in newly-diagnosed adult coeliac disease patients. Aliment Pharmacol Ther 2000 Jan;14(1):35-43. DOI: 10.1046/j.1365-2036.2000.00671.x
19. Mora S, Barera G, Ricotti A, Weber G, Bianchi C, Chiumello G. Reversal of low bone density with a gluten-free diet in children and adolescents with celiac disease. Am J Clin Nutr 1998 Mar;67(3):477-81.
20. Cellier C, Flobert C, Cormier C, Roux C, Schmitz J. Severe osteopenia in symptom-free adults with a childhood diagnosis of coeliac disease. Lancet 2000 Mar 4;355(9206):806. DOI: 10.1016/S0140-6736(99)04855-2
21. Turner J, Pellerin G, Mager D. Prevalence of metabolic bone disease in children with celiac disease is independent of symptoms at diagnosis. J Pediatr Gastroenterol Nutr 2009 Nov;49(5):589-93. DOI: 10.1097/MPG.0b013e31819ca18e
22. Lewis NR, Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. British Society of Gastroenterology 2007.
23. Lewis NR, Scott BB. Should patients with coeliac disease have their bone mineral density measured? Eur J Gastroenterol Hepatol 2005 Oct;17(10):1065-70. DOI: 10.1097/00042737-200510000-00009
24. Juhasz M, Kocsis D, Zagoni T, Miheller P, Herszenyi L, Tulassay Z. [Retrospective evaluation of the ten-year experience of a single coeliac centre]. Orv Hetil 2012 May 20;153(20):776-85.
25. Mora S, Weber G, Barera G, Bellini A, Pasolini D, Prinster C, Bianchi C, Chiumello G. Effect of gluten-free diet on bone mineral content in growing patients with celiac disease. Am J Clin Nutr 1993 Feb;57(2):224-8.

The Medicalisation of Criminal Behaviour: A Unifying Approach

Jonathan Rogers, School of Clinical Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, CB2 0SP, England, UK


Quand tu sauras mon crime et le sort qui m’accable,
Je n’en mourrai pas moins, j’en mourrai plus coupable.

Jean Racine (1639–1699), Phèdre1

Phèdre is a tragedy which explores the relationship between moral culpability and responsibility for one’s actions by examining the incestuous love of a queen for her step-son, a passion that is apparently imputed to her by a vengeful deity. What is fascinating for the purposes of our discussion is the dynamic interplay between the portrayals of Phèdre’s infatuation both as an illness and simultaneously as a crime, for this is essentially the same question we must consider in deciding to what extent a malady excuses behaviour that contravenes society’s judicial expectations. While this was doubtless an intriguing consideration for a seventeenth century French dramatist, it is all the more pertinent for us today given the extent of medicalisation that has occurred in recent decades across many spheres of society. In terms of psychiatry, this may be illustrated merely with reference to the DSM, which between its first edition in 1952 and the fourth revision fifty-two years later has more than tripled the number of conditions it identifies, taking the total from 112 to more than 370 today [1]. This inexorable rise has led certain commentators to question the extent to which this phenomenon is justified, particularly where it impinges on the realm of moral accountability. This is exemplified in an article by the sociologist Frank Furedi entitled The seven deadly personality disorders, in which he describes how all of those vices that the Catholic Church once taught to be mortal sins are now considered by Western culture to be addictive illnesses, with the sole exception of pride, which is thought to be a virtue, the helpful antidote to low self-esteem [2]. This issue is one of eminent importance to the forensic psychiatrist, who may be obliged to stand as an expert witness and give evidence on a defendant’s mental state, potentially obviating the accusation that they had the mens rea for a crime. This is particularly the case in homicide, where mental illness can reduce a verdict from murder to manslaughter, but it is of more general significance in the verdict of ‘not guilty by reason of insanity’. Thus, this essay shall concern itself with a consideration of the current theories on which medico-legal practice seems to be predicated, before examining a possible alternative to this model and the congruence of this with a broader philosophical perspective, concluding with some speculation as to the implications of this concept for clinical practice and for society.


1. Peter W. Halligan, Christopher Bass, David A. Oakley. Malingering and Illness Deception. s.l. : OUP, 2003.
2. Furedi, Frank. The seven deadly personality disorders. Spiked Online. [Online] 12 March 2008. [Cited: 26 11 2011.]
3. Parsons, Talcott. The Social System. 1951.
4. The Monoamine Oxidase A (MAOA) Genetic Predisposition to Impulsive Violence: Is It Relevant to Criminal Trials? Baum, Matthew L. 2011, Neuroethics.
5. Self-Control, Social Consequences, and Criminal Behavior: Street Youth and the General Theory of Crime. Baron, Stephen W. 4, 2003, Journal of Research in Crime and Delinquency, Vol. 40, pp. 403-425.
6. J.H. Stone, M. Roberts, J. O'Grady & A.V. Taylor with K. O'Shea. Faulk's Basic Forensic Psychiatry Third Edition. s.l. : Blackwell Science, 2000.
7. Legal Responsibility and Mental Illness. Baur, Alfred K. 1, 1962, Northwestern University Law Review, Vol. 57.
8. Neuroscience, Choice, and the Free Will Debate. Shephard, Jason and Reuter, Shane. 3, 2012, AJOB Neuroscience, Vol. 3.
9. United Nations Office on Drugs and Crime. Persons Detained. United Nations Office on Drugs and Crime. [Online] [Cited: 26 11 2011.]

Case Report: Left knee pain in a young female athlete

Jonathan Packer, University of Birmingham, Birmingham, UK

Clinical History

A 14 year old girl was seen in clinic after an injury whilst playing rugby. Although her description was vague, she intimated that a valgus stress had been put on her left leg and described being tackled in rugby practice. She fell on her left knee and heard an audible cracking or ‘pop’ sound, experiencing immediate pain and swelling of the joint. She had no significant past medical history and was taking no regular medication.


1. Schmitgen. G.F, Utukuri. M.M. Arthroscopic treatment of tibial spine fractures in children: a review of three cases. 2000, Knee 7(2), 115-119. doi:10.1016/S0968-0160(00)00037-5

2. Moore. K.L, Dalley. A.F, Agur. A.M.R – Clinically Orientated Anatomy 6th Edition – Lippincott Williams & Wilkins. 2010.

3. Clifford R. Wheeless III, James A. Nunley, II, MD and James R. Urbaniak, MD - Wheeless Textbook of Orthopaedics available at :

4. Solomon. L, Warwick. D.J, Nayagam. S - Appley’s Concise System of Orthopaedics and Fractures - Third Edition, Published by Hodder Arnold, 2005.

5. Willis RB, Blokker C, Stoll TM, Paterson DC, Galpin RD. Long-term follow-up of anterior tibial eminence fractures. 1993, Journal of Paediatric Orthopaedics 13(3):361-4.

6. Baxter MP, Wiley JJ. ‘Fractures of the tibial spine in children. An evaluation of knee stability’. 1988, Journal of Bone and Joint Surgery Br. 70(2):228-30.

7. Molander ML, Wallin G, Wikstad I. ‘Fracture of the intercondylar eminence of the tibia: a review of 35 patients’. 1981, Journal of Bone and Joint Surgery Br. 63-B(1):89-91.

The need for a Liaison and Mediation Service to assist doctors and their young patients who refuse treatment

Zenon Stavrinides, Tutor in Medical Ethics, University of Leeds, UK


This paper attempts four things:
(1) to identify uncertainties and ambiguities in English law and medical guidance concerning the circumstances in which a competent adolescent patient who refuses a clinically indicated treatment can be overruled by a court of law in their own best interests;
(2) to clarify the nature and sources of two opposing attitudes towards the matter of the extent and limits of an adolescent patient’s right to refuse clinically indicated treatment;
(3) to argue for the need to set up in hospitals a Liaison and Mediation Service to facilitate communication between an adolescent who refuses treatment and their doctors with a view to developing, if possible, an agreed decision; and
(4) to outline a widened conception of an adolescent’s best interests which includes, besides the restoration of their health, respect for their personality and autonomy, acknowledgement of their right to be informed about the treatment proposed to them, recognition of their capacity to gain considerable understanding of the nature and consequences of the treatment and any alternatives, and also acceptance by doctors and judges of their ability to make their own decisions which is commensurate to the degree of intellectual and emotional maturity they have attained.


1. Shaw M. (2001) Competence and consent to treatment in children and adolescents. Advances in Psychiatric Treatment, 7:150-9. DOI: 10.1192/apt.7.2.150
2. All England Law Reports [1992] 624, 4.
3. Brooks,WG Jr, Bahar-Posey L, Weathers LS, Pardue W (1994) Children’s consent to treatment, British Medical Journal, 309:807.
4. Alderson P, Montgomery J (1996) Health care choices: making decisions with children. Chapter 5 and passim.
5. United Nations General Assembly Resolution 44/25, 1989. Available at
6. Committee on the Rights of the Child (2009) General Comment No. 12 on the right of the child to be heard. Available at
7. Department of Health (2009) Reference guide to consent for examination on treatment, 2nd ed. Available from
8. General Medical Council (2007) 0-18 Years: Guidance for all doctors, para. 12. Available from
9. Children Act 1989. Available from
10. Alderson P (1992) In the genes or in the stars? Children’s competence to consent. Journal of Medical Ethics, Vol. 18, No. 3. DOI:10.1136/jme.18.3.119
11. PALS web site available from
12. 2009 Supreme Court of Canada 87.
13. Human Rights Act 1998. Available from
14. UN Convention on the Rights of the Child is available at
15. Taylor, R. (2007) Reversing the retreat from Gillick?: R (Axon) v Secretary of State for Health. Child and Family Law Quarterly, 19 (1) 81.
16. Choudhry, S, Fenwick, H (2005) Taking the rights of parents and children seriously: Confronting the welfare principle under the Human Rights Act. Oxford Journal of Legal Studies 25(3), 453-492.
17. Cave E (2011) Maximisation of minors’ capacity. Child and Family Law Quarterly, Vol. 23, No. 4.

Syndicate content